These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 36056913)
1. A Pilot Trial of Thymalfasin (Thymosin-α-1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection. Shehadeh F; Benitez G; Mylona EK; Tran QL; Tsikala-Vafea M; Atalla E; Kaczynski M; Mylonakis E J Infect Dis; 2023 Jan; 227(2):226-235. PubMed ID: 36056913 [TBL] [Abstract][Full Text] [Related]
2. Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells. Liu Y; Pan Y; Hu Z; Wu M; Wang C; Feng Z; Mao C; Tan Y; Liu Y; Chen L; Li M; Wang G; Yuan Z; Diao B; Wu Y; Chen Y Clin Infect Dis; 2020 Nov; 71(16):2150-2157. PubMed ID: 32442287 [TBL] [Abstract][Full Text] [Related]
3. Thymosin Alpha-1 Has no Beneficial Effect on Restoring CD4+ and CD8+ T Lymphocyte Counts in COVID-19 Patients. Wang Z; Chen J; Zhu C; Liu L; Qi T; Shen Y; Zhang Y; Xu L; Li T; Qian Z; Steinhart CR; Lu H Front Immunol; 2021; 12():568789. PubMed ID: 34149679 [TBL] [Abstract][Full Text] [Related]
4. Thymosin alpha 1 - Reimagine its broader applications in the immuno-oncology era. Mao L Int Immunopharmacol; 2023 Apr; 117():109952. PubMed ID: 36871535 [TBL] [Abstract][Full Text] [Related]
5. Thymosin alpha 1 restores the immune homeostasis in lymphocytes during Post-Acute sequelae of SARS-CoV-2 infection. Minutolo A; Petrone V; Fanelli M; Maracchioni C; Giudice M; Teti E; Coppola L; Sorace C; Iannetta M; Tony Miele M; Bernardini S; Mastino A; Sinibaldi Vallebona P; Balestrieri E; Andreoni M; Sarmati L; Grelli S; Garaci E; Matteucci C Int Immunopharmacol; 2023 May; 118():110055. PubMed ID: 36989892 [TBL] [Abstract][Full Text] [Related]
6. Thymalfasin for the treatment of chronic hepatitis B. Chien RN; Liaw YF Expert Rev Anti Infect Ther; 2004 Feb; 2(1):9-16. PubMed ID: 15482167 [TBL] [Abstract][Full Text] [Related]
7. Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials. Dinetz E; Lee E Altern Ther Health Med; 2024 Jan; 30(1):6-12. PubMed ID: 38308608 [TBL] [Abstract][Full Text] [Related]
8. Gender-associated difference following COVID-19 virus infection: Implications for thymosin alpha-1 therapy. Li X; Liu L; Yang Y; Yang X; Wang C; Li Y; Ge Y; Shi Y; Lv P; Zhou H; Luo P; Huang S Int Immunopharmacol; 2021 Jan; 90():107022. PubMed ID: 33160854 [TBL] [Abstract][Full Text] [Related]
9. Thymosin α1 modulated the immune landscape of COVID-19 patients revealed by single-cell RNA and TCR sequencing. Bai H; Liang L; Qi X; Xu Y; Liu Y; Ren D; Cai Z; Mao W; Wang X; Qin H; Hu F; Shi B Int Immunopharmacol; 2023 Nov; 124(Pt B):110983. PubMed ID: 37769533 [TBL] [Abstract][Full Text] [Related]
10. A pilot study of thymosin alpha1 therapy for chronic hepatitis B patients. Arase Y; Tsubota A; Suzuki Y; Suzuki F; Kobayashi M; Someya T; Akuta N; Hosaka T; Saitoh S; Ikeda K; Kobayashi M; Kumada H Intern Med; 2003 Oct; 42(10):941-6. PubMed ID: 14606705 [TBL] [Abstract][Full Text] [Related]
11. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Wu J; Zhou L; Liu J; Ma G; Kou Q; He Z; Chen J; Ou-Yang B; Chen M; Li Y; Wu X; Gu B; Chen L; Zou Z; Qiang X; Chen Y; Lin A; Zhang G; Guan X Crit Care; 2013 Jan; 17(1):R8. PubMed ID: 23327199 [TBL] [Abstract][Full Text] [Related]
12. A pilot study of the safety and efficacy of thymosin alpha 1 in augmenting immune reconstitution in HIV-infected patients with low CD4 counts taking highly active antiretroviral therapy. Chadwick D; Pido-Lopez J; Pires A; Imami N; Gotch F; Villacian JS; Ravindran S; Paton NI Clin Exp Immunol; 2003 Dec; 134(3):477-81. PubMed ID: 14632754 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of Thymosin Alpha 1 in the Treatment of COVID-19: A Multicenter Cohort Study. Liu J; Shen Y; Wen Z; Xu Q; Wu Z; Feng H; Li Z; Dong X; Huang S; Guo J; Zhang L; Chen Y; Li W; Zhu W; Du H; Liu Y; Wang T; Chen L; Teboul JL; Annane D; Chen D Front Immunol; 2021; 12():673693. PubMed ID: 34408744 [TBL] [Abstract][Full Text] [Related]
14. Thymosin alpha1 use in adult COVID-19 patients: A systematic review and meta-analysis on clinical outcomes. Shang W; Zhang B; Ren Y; Wang W; Zhou D; Li Y Int Immunopharmacol; 2023 Jan; 114():109584. PubMed ID: 36527881 [TBL] [Abstract][Full Text] [Related]
15. A pilot trial of Thymalfasin (Ta1) to prevent covid-19 infection and morbidities in renal dialysis patients: Preliminary report. Tuthill CW; Awad A; Parrigon M; Ershler WB Int Immunopharmacol; 2023 Apr; 117():109950. PubMed ID: 36881981 [TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of Thymosin α1 in the treatment of hepatitis B virus-related acute-on-chronic liver failure: a randomized controlled trial. Chen JF; Chen SR; Lei ZY; Cao HJ; Zhang SQ; Weng WZ; Xiong J; Lin DN; Zhang J; Zheng YB; Gao ZL; Lin BL Hepatol Int; 2022 Aug; 16(4):775-788. PubMed ID: 35616850 [TBL] [Abstract][Full Text] [Related]
17. Immune-Enhancing Treatment among Acute Necrotizing Pancreatitis Patients with Metabolic Abnormalities: A Huang X; Mao W; Hu X; Qin F; Zhao H; Zhang A; Wang X; Stoppe C; Zhou D; Ke L; Ni H; Gut Liver; 2024 Sep; 18(5):906-914. PubMed ID: 38356344 [TBL] [Abstract][Full Text] [Related]
18. Thymosin α1 therapy in critically ill patients with COVID-19: A multicenter retrospective cohort study. Wu M; Ji JJ; Zhong L; Shao ZY; Xie QF; Liu ZY; Wang CL; Su L; Feng YW; Liu ZF; Yao YM Int Immunopharmacol; 2020 Nov; 88():106873. PubMed ID: 32795897 [TBL] [Abstract][Full Text] [Related]
19. The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis. Peng D; Xing HY; Li C; Wang XF; Hou M; Li B; Chen JH BMC Gastroenterol; 2020 Oct; 20(1):348. PubMed ID: 33076834 [TBL] [Abstract][Full Text] [Related]
20. Effect of thymosin alpha-1 on subpopulations of Th1, Th2, Th17, and regulatory T cells (Tregs) in vitro. Yang X; Qian F; He HY; Liu KJ; Lan YZ; Ni B; Tian Y; Fu XL; Zhang J; Shen ZG; Li J; Yin Y; Li JT; Wu YZ Braz J Med Biol Res; 2012 Jan; 45(1):25-32. PubMed ID: 22245858 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]